Establishment Labs Announces Participation in Two Upcoming Investment Conferences
Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, today announced its participation in two upcoming investment conferences.
Juan José Chacón-Quirós, Chief Executive Officer and Founder, and Raj Denhoy, Chief Financial Officer, will participate in the 2023 Jefferies London Healthcare Conference held November 14-16, 2023. Mr. Chacón-Quirós and Mr. Denhoy are scheduled to speak in person to conference attendees on Tuesday, November 14 at 4:30-4:55 PM GMT.
Mr. Denhoy will also participate in the Stephens Annual Investment Conference, being held on November 14-16, 2023. Mr. Denhoy is scheduled to speak in person to conference attendees on Thursday, November 16, 2023, at 10:00 AM CT.
Live webcasts of the presentations will be available to all interested parties on the Establishment Labs investor relations website at https://investors.establishmentlabs.com/. Archived versions of the webcasts will be available on the same website following the completion of the events.
About Establishment Labs
Establishment Labs Holdings Inc. is a global medical technology company dedicated to improving women’s health and wellness through the power of science, engineering, and technology. The Company offers a portfolio of Femtech solutions for breast health, breast aesthetics and breast reconstruction. The over three million Motiva® devices Establishment Labs has delivered to plastic and reconstructive surgeons since 2010 have created a new standard for safety and patient satisfaction in the over 85 countries in which they are available. The Motiva Flora® tissue expander is used to improve outcomes in breast reconstruction following breast cancer and it is the only regulatory-approved expander in the world with an integrated port using radio-frequency technology that is MRI conditional. Mia Femtech™, Establishment Lab’s unique minimally invasive experience for breast harmony, is the Company’s most recent breakthrough innovation. These solutions are supported by over 200 patent applications in 25 separate patent families worldwide and over 50 scientific studies and publications in peer reviewed journals. Establishment Labs manufactures at two facilities in Costa Rica compliant with all applicable regulatory standards under ISO13485:2016 and FDA 21 CFR 820 under the MDSAP program. In 2018, the Company received an investigational device exemption (IDE) from the FDA for Motiva Implants® and began a clinical trial to support regulatory approval in the United States. Please visit our website for additional information at www.establishmentlabs.com.
Establishment Labs' Motiva silicone gel-filled implants are currently not approved for commercial distribution in the United States. The Company’s implants are undergoing PMA clinical investigation pursuant to U.S. FDA regulations for investigational medical devices.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231109182253/en/
Establishment Labs Holdings Inc Stock
With 9 Buy predictions and not the single Sell prediction the community is currently very high on Establishment Labs Holdings Inc.
As a result the target price of 55 € shows a slightly positive potential of 10.0% compared to the current price of 50.0 € for Establishment Labs Holdings Inc.
